drugset
drugset / Trial / NCT03944577

Impact of Evolocumab in Cardiac Transplant Patients With CAV

NCT03944577 ↗

Phase 2 Completed 26 enrolled University of Nebraska Amgen · collab
NaSingle-groupOpen-labelTreatment

Summary

Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary objective of this study is to measure the impact of PCSK9-inhibitors on serum LDL in heart transplant patients with CAV after 12 weeks compared to baseline.

Timeline

Start
2019-07-15
Primary completion
2023-03-28
Completion
2023-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody 140 mg Subcutaneous

Indications

No indication recorded.